Literature DB >> 20096151

Management of behavioral problems in Alzheimer's disease.

Serge Gauthier1, Jeffrey Cummings, Clive Ballard, Henry Brodaty, George Grossberg, Philippe Robert, Constantine Lyketsos.   

Abstract

Alzheimer's disease (AD) is a complex progressive brain degenerative disorder that has effects on multiple cerebral systems. In addition to cognitive and functional decline, diverse behavioral changes manifest with increasing severity over time, presenting significant management challenges for caregivers and health care professionals. Almost all patients with AD are affected by neuropsychiatric symptoms at some point during their illness; in some cases, symptoms occur prior to diagnosis of the dementia syndrome. Further, behavioral factors have been identified, which may have their origins in particular neurobiological processes, and respond to particular management strategies. Improved clarification of causes, triggers, and presentation of neuropsychiatric symptoms will guide both research and clinical decision-making. Measurement of neuropsychiatric symptoms in AD is most commonly by means of the Neuropsychiatric Inventory; its utility and future development are discussed, as are the limitations and difficulties encountered when quantifying behavioral responses in clinical trials. Evidence from clinical trials of both non-pharmacological and pharmacological treatments, and from neurobiological studies, provides a range of management options that can be tailored to individual needs. We suggest that non-pharmacological interventions (including psychosocial/psychological counseling, interpersonal management and environmental management) should be attempted first, followed by the least harmful medication for the shortest time possible. Pharmacological treatment options, such as antipsychotics, antidepressants, anticonvulsants, cholinesterase inhibitors and memantine, need careful consideration of the benefits and limitations of each drug class.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096151     DOI: 10.1017/S1041610209991505

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  81 in total

1.  [Psychosocial interventions and caregiver support].

Authors:  M Hüll; I Wernher
Journal:  Nervenarzt       Date:  2010-07       Impact factor: 1.214

2.  Citalopram for agitation in Alzheimer's disease: design and methods.

Authors:  Lea T Drye; Zahinoor Ismail; Anton P Porsteinsson; Paul B Rosenberg; Daniel Weintraub; Christopher Marano; Gregory Pelton; Constantine Frangakis; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; D P Devanand; Jerome Yesavage; Jacobo E Mintzer; Lon S Schneider; Bruce G Pollock; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012-02-01       Impact factor: 21.566

3.  Behavioral disturbance in dementia.

Authors:  Abhilash K Desai; Lori Schwartz; George T Grossberg
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

4.  Latent Classes of Neuropsychiatric Symptoms in NACC Controls and Conversion to Mild Cognitive Impairment or Dementia.

Authors:  Jeannie-Marie S Leoutsakos; Sarah N Forrester; Constantine G Lyketsos; Gwenn S Smith
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

5.  Routine cognitive screening in a neurology practice: Effect on physician behavior.

Authors:  Michael Rosenbloom; Soo Borson; Terry Barclay; Leah R Hanson; Ann Werner; Logan Stuck; John McCarten
Journal:  Neurol Clin Pract       Date:  2016-02

6.  Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial.

Authors:  Geke A H van den Elsen; Amir I A Ahmed; Robbert-Jan Verkes; Cees Kramers; Ton Feuth; Paul B Rosenberg; Marjolein A van der Marck; Marcel G M Olde Rikkert
Journal:  Neurology       Date:  2015-05-13       Impact factor: 9.910

7.  OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE.

Authors:  James E Galvin
Journal:  Neurodegener Dis Manag       Date:  2012-06

8.  A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia.

Authors:  Zahinoor Ismail; Chetachi A Emeremni; Patricia R Houck; Sati Mazumdar; Jules Rosen; Tarek K Rajji; Bruce G Pollock; Benoit H Mulsant
Journal:  Am J Geriatr Psychiatry       Date:  2013-01-02       Impact factor: 4.105

Review 9.  Late-onset Alzheimer Disease.

Authors:  Gil D Rabinovici
Journal:  Continuum (Minneap Minn)       Date:  2019-02

Review 10.  Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes.

Authors:  Amir A Sepehry; Philip E Lee; Ging Yuek R Hsiung; B Lynn Beattie; Claudia Jacova
Journal:  Drugs Aging       Date:  2012-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.